TNFA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TNFA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, TNF Pharmaceuticals's Enterprise Value is $-9.05 Mil. TNF Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-11.38 Mil. Therefore, TNF Pharmaceuticals's EV-to-EBIT ratio for today is 0.80.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, TNF Pharmaceuticals's Enterprise Value is $-9.05 Mil. TNF Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-11.38 Mil. Therefore, TNF Pharmaceuticals's EV-to-EBITDA ratio for today is 0.80.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, TNF Pharmaceuticals's Enterprise Value is $-9.05 Mil. TNF Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil. Therefore, TNF Pharmaceuticals's EV-to-Revenue ratio for today is .
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, TNF Pharmaceuticals's Enterprise Value is $-9.05 Mil. TNF Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-10.15 Mil. Therefore, TNF Pharmaceuticals's EV-to-FCF ratio for today is 0.89.
The historical data trend for TNF Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TNF Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Enterprise Value | - | 217.08 | 40.85 | 11.34 |
TNF Pharmaceuticals Quarterly Data | ||||||||||||||||||
Mar20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Enterprise Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
20.20 | 11.34 | 3.91 | -8.25 | -6.20 |
For the Biotechnology subindustry, TNF Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TNF Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where TNF Pharmaceuticals's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
TNF Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 15.669459 | + | 0.549 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.049 | + | 0 | - | 4.923 |
= | 11.34 |
TNF Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as
Enterprise Value (Q: Sep. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 4.00464 | + | 0.422 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.018 | + | 0 | - | 10.642 |
= | -6.20 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TNF Pharmaceuticals (NAS:TNFA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
TNF Pharmaceuticals's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | -9.048 | / | -11.381 | |
= | 0.80 |
TNF Pharmaceuticals's current Enterprise Value is $-9.05 Mil.
TNF Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.38 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
TNF Pharmaceuticals's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | -9.048 | / | -11.381 | |
= | 0.80 |
TNF Pharmaceuticals's current Enterprise Value is $-9.05 Mil.
TNF Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.38 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
TNF Pharmaceuticals's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | -9.048 | / | 0 | |
= |
TNF Pharmaceuticals's current Enterprise Value is $-9.05 Mil.
TNF Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.
TNF Pharmaceuticals's EV-to-FCF for today is:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | -9.048 | / | -10.146 | |
= | 0.89 |
TNF Pharmaceuticals's current Enterprise Value is $-9.05 Mil.
TNF Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of TNF Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Rivard | officer: EVP of Operations, GC | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Joshua Silverman | director | IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
Caroline C Williams | 10 percent owner | 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
Adam Kaplin | officer: Chief Scientific Officer | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Jude Uzonwanne | director | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Craig Eagle | director | POST OFFICE BOX 4590, NEW YORK NY 10163 |
Chapman Christopher C Jr | director, officer: President, Chief Med. Officer | C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814 |
Ian Rhodes | officer: Interim CFO | 1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824 |
Stuart M Benson | officer: Chief Financial Officer | EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118 |
Hudson Bay Capital Management Lp | 10 percent owner | 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Sander Gerber | 10 percent owner | C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Robert C Schroeder | director | 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724 |
Howard Yeaton | officer: CEO, CFO | 79 LLOYD ROAD, HOHOKUS NJ 07423 |
Tarbox Richard C Iii | director | AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
Christopher C Schreiber | director | AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
From GuruFocus
By Business Wire • 08-02-2023
By Business Wire • 07-31-2023
By GuruFocus Research • 02-08-2024
By Business Wire Business Wire • 03-02-2023
By Business Wire • 03-05-2024
By GuruFocus Research • 02-08-2024
By Business Wire • 12-19-2024
By Business Wire Business Wire • 04-12-2023
By Business Wire Business Wire • 03-20-2023
By Business Wire • 07-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.